Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients

被引:29
作者
Jing, Sun [1 ]
Kezhou, Yu [1 ]
Hong, Zhang [1 ]
Qun, Wang [1 ]
Rong, Wang [1 ]
机构
[1] Shandong Univ, Dept Kidney, Shandong Prov Hosp, Jinan 250021, Peoples R China
关键词
peritoneal dialysis; peritoneal fibrosis; renin-angiotensin system; ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; VASCULAR-PERMEABILITY FACTOR; MESOTHELIAL CELLS; RECEPTOR BLOCKERS; ACE-INHIBITORS; FACTOR-BETA; MEMBRANE; MECHANISMS; GLUCOSE;
D O I
10.1111/j.1440-1797.2009.01162.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: Long-term peritoneal dialysis (PD) may lead to peritoneal fibrosis and ultrafiltration failure. It had been demonstrated that the renin-angiotensin system (RAS) plays a key role in the regulation of peritoneal function in rats on PD. We investigated the effects of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) on long-term PD patients. Methods: We analyzed data from 66 patients treated with PD therapy at our centre for at least 12 months retrospectively, during which time at least two peritoneal equilibration tests (PET) were performed. Thirty-eight patients were treated with ACE/angiotensin II (AII) inhibitors (ACE/ARB group); the other 28 received none of the above drugs during the entire follow up (control group). The expression of fibronectin, transforming growth factor-beta 1 (TGF-beta 1), Aquaporin1 (AQP1) and vascular endothelial growth factor (VEGF) in the overnight effluent were examined by enzyme-linked immunosorbent assay. Results: The demographic data of the two groups showed no difference during the study. No difference between the groups was found with respect to residual renal function (RRF) at the start for both groups by the end of follow up, decreased in the vast majority of patients from both groups (P = 0.014). After 12 months, a significant difference in ultrafiltration was found between the two groups: in the control group it had decreased, while it had not changed in the ACE/ARB group (P < 0.05). In comparison with the baseline level, expression of fibronectin, TGF-beta 1 and VEGF in dialysate effluent were significantly increased except for AQP1 in the control group (P < 0.05), but not in the ACE/ARB group (P > 0.05). Conclusion: The findings suggest that ACE/AII inhibitors appeared to have a slower rate of decline in ultrafiltration and RRF, effectively protect against peritoneal fibrosis in long-term peritoneal dialysis. Long-term follow up seems to be required to draw more conclusions.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 50 条
  • [41] Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
    Sun, Chiao-Yin
    Hsieh, Yu-Ting
    Lu, Shang-Chieh
    Huang, Chi-Ying F.
    [J]. PHARMACEUTICALS, 2025, 18 (02)
  • [42] Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review
    Kim, Gaeun
    Kim, Juyoung
    Lim, Yoo Li
    Kim, Moon Young
    Baik, Soon Koo
    [J]. HEPATOLOGY INTERNATIONAL, 2016, 10 (05) : 819 - 828
  • [43] Tanshinone IIA Attenuates Peritoneal Fibrosis through Inhibition of Fibrogenic Growth Factors Expression in Peritoneum in a Peritoneal Dialysis Rat Model
    Jiang Chunming
    Zhang Miao
    Sun Cheng
    Tao Nana
    Zhu Wei
    Cao Dongwei
    Feng Yuan
    [J]. RENAL FAILURE, 2011, 33 (03) : 355 - 362
  • [44] A Review on Major Pathways Leading to Peritoneal Fibrosis in Patients Receiving Continuous Peritoneal Dialysis
    Taheri, Sogand
    Thiagaraj, Suvedha S.
    Shukla, Twisha S.
    Gutlapalli, Sai Dheeraj
    Farhat, Hadi
    Muthiah, Kanmani
    Pallipamu, Namratha
    Hamid, Pousette
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [45] Treatment of Established Peritoneal Fibrosis by Gene Transfer of Smad7 in a Rat Model of Peritoneal Dialysis
    Sun, Yanyan
    Zhu, Fengxin
    Yu, Xueqing
    Nie, Jing
    Huang, Fengxian
    Li, Xiaoyan
    Luo, Ning
    Lan, Hui Yao
    Wang, Yongtao
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2009, 30 (01) : 84 - 94
  • [46] Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction
    Maitland-van der Zee, Anke-Hilse
    van Wieren-de Wijer, Diane B. M. A.
    de Boer, Anthonius
    Kroon, Abraham A.
    de Leeuw, Peter W.
    Schiffers, Paul
    Janssen, Rob G. J. H.
    Psaty, Bruce M.
    van Duijn, Cornelia M.
    Stricker, Bruno H. Ch
    Klungel, Olaf H.
    [J]. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2011, 12 (03) : 208 - 214
  • [47] The Role of Cathepsin B in Peritoneal Fibrosis due to Peritoneal Dialysis
    Sung, Su Ah
    Kim, Dong Hee
    Oh, Kook-Hwan
    Han, Sang Youb
    Han, Kum Hyun
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY, 2019, 2019
  • [48] Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
    Lu, Jing
    Gao, Jie
    Sun, Jing
    Wang, Haiping
    Sun, Huijuan
    Huang, Qian
    Zhang, Yao
    Zhong, Shuo
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [49] Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients
    Oh, KH
    Margetts, PJ
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2005, 28 (02) : 129 - 134
  • [50] TREATMENT WITH ANGIOTENSIN II INHIBITORS AND RESIDUAL RENAL FUNCTION IN PERITONEAL DIALYSIS PATIENTS
    Kolesnyk, Inna
    Noordzij, Marlies
    Dekker, Friedo W.
    Boeschoten, Elisabeth W.
    Krediet, Raymond T.
    [J]. PERITONEAL DIALYSIS INTERNATIONAL, 2011, 31 (01): : 53 - 59